Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
08 Maggio 2024 - 7:48AM
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive
Scheme Obligations
COPENHAGEN, Denmark, May 8,
2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the
initiation of a new share buy-back program, under which the Company
intends to buy back up to 162,288 of its own shares. The purpose of
the share buy-back program is to meet the Company’s obligations
arising from the share-based incentive programs for the Board of
Directors and Executive Management, in accordance with the
Company’s remuneration policy.
The share buy-back program is initiated pursuant
to the authorization granted at the annual general meeting on April
16, 2024, according to which the Company may purchase up to 10 % of
the Company's share capital for the time being.
The share buy-back program will be executed in
accordance with Regulation (EU) No. 596/2014 of the European
Parliament and of the Council of 16 April 2014 on market abuse and
supplementing Regulation (EU) 2016/1052 of 8 March 2016, which
together constitute the Safe Harbour Regulation.
Bavarian Nordic A/S has appointed Danske Bank
A/S Lead Manager of the program. Danske Bank A/S will buy back
shares on behalf of Bavarian Nordic A/S and make decisions on
trading with Bavarian Nordic A/S' shares independently and without
influence of Bavarian Nordic A/S.
The program will be implemented in accordance
with the authorization within the following scope:
- A maximum of 162,288 shares will be purchased within the
duration of the program.
- The maximum consideration for Bavarian Nordic A/S-shares
purchased within the duration of the program is DKK 40 million.
However, based on the closing price of Bavarian Nordic’s share on
Nasdaq Copenhagen A/S on May 7, 2024, the total consideration is
expected to be in the level of DKK 26 million.
- The program terminates at the latest on May 21, 2024.
- The maximum number of shares, which may be purchased per
trading day, shall not exceed 25% of the average daily volume of
shares in the Company traded on Nasdaq Copenhagen A/S in the
preceding 20 trading days.
- The shares may not be purchased at a price which is higher than
the higher of the following:
- The price of the last independent trade.
- The highest current independent purchase bid on Nasdaq
Copenhagen A/S.
Bavarian Nordic A/S may terminate the program at
any time. If the Company determines to terminate the program, the
Company will give notice hereof.
About Bavarian NordicBavarian
Nordic is a fully integrated vaccine company with a mission to
protect and save lives through innovative vaccines. We are a global
leader in smallpox and mpox vaccines, supplied to governments to
enhance public health preparedness and have a strong portfolio of
vaccines for travelers and endemic diseases. For more information
visit www.bavarian-nordic.com.
Forward-looking statements This
announcement includes forward-looking statements that involve
risks, uncertainties and other factors, many of which are outside
of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking
statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance
and/or other information that is not historical information. All
such forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made,
except as required by law.
ContactsEurope: Rolf Sass
Sørensen, Vice President Investor Relations,
rss@bavarian-nordic.com, Tel: +45 61 77 47 44 US: Graham Morrell,
graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 13 / 2024
Grafico Azioni Bavarian Nordic AS (TG:BV3)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Bavarian Nordic AS (TG:BV3)
Storico
Da Nov 2023 a Nov 2024